Growth Metrics

Vivos Therapeutics (VVOS) Other Working Capital Changes (2020 - 2025)

Vivos Therapeutics has reported Other Working Capital Changes over the past 6 years, most recently at -$440000.0 for Q4 2025.

  • Quarterly Other Working Capital Changes fell 397.3% to -$440000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$514000.0 through Dec 2025, down 407.78% year-over-year, with the annual reading at -$514000.0 for FY2025, 407.78% down from the prior year.
  • Other Working Capital Changes was -$440000.0 for Q4 2025 at Vivos Therapeutics, down from -$7000.0 in the prior quarter.
  • Over five years, Other Working Capital Changes peaked at $1.1 million in Q2 2021 and troughed at -$803000.0 in Q3 2021.
  • The 5-year median for Other Working Capital Changes is -$16000.0 (2023), against an average of -$1700.0.
  • The largest YoY upside for Other Working Capital Changes was 24557.83% in 2021 against a maximum downside of 22468.42% in 2021.
  • A 5-year view of Other Working Capital Changes shows it stood at $352000.0 in 2021, then crashed by 187.5% to -$308000.0 in 2022, then surged by 285.06% to $570000.0 in 2023, then crashed by 74.04% to $148000.0 in 2024, then plummeted by 397.3% to -$440000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Other Working Capital Changes are -$440000.0 (Q4 2025), -$7000.0 (Q3 2025), and $332000.0 (Q2 2025).